Jonathan Javitt's guest appearances

Jonathan Javitt

StartUp Health NOW Podcast

Empowered Patient Podcast

StartUp Health NOW!

Biotech 2050 Podcast

Seth Lederman

Dave Chase

Mike Clayman

Brian Culley

James Mackay

Anish Sebastian

Karen Zaderej

Bronwyn Spira

Jim Woody

Paula Ragan

Steve Case

Sanjay Gupta

Sean Tucker

Matt Wilson

Robert Gould

OwlTail

Dr. Javitt has played leadership roles in seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned to lead the White House policy for universal adoption of Health IT and establishment of the Office of the National Coordinator. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins Medical School. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited by more than 16,000 people.

43. From health economics to COVID19 treatment, Jonathan Javitt, Co-Founder and CEO, NeuroRx Pharma

Dr. Jonathan Javitt, Founder, Chairman and CEO, NeuroRx talks about drawing on their work developing novel therapeutics for bipolar depression and respiratory disease to focus on a therapy, aviptadil also known as ZYESAMI, for critical COVID-19 especially those with advanced comorbidities. This peptide hormone VIP enters the alveolar type II rare cell in the lung and blocks the replication of the SARs-CoV-2 virus and the production of inflammatory cytokines. Available through the FDA Expanded Access protocol, this drug is showing a nine-fold difference in survival and recovery from respiratory failure compared to patients with best available standard of care. @neurorxpharma #aviptadil #RLF-100 #ZYESAMI #coronavirus #COVID19 #drugdevelopment #pandemic $NRXP NeuroRxPharma.com Download the transcript here

Dr. Jonathan Javitt, Founder, Chairman and CEO, NeuroRx talks about drawing on their work developing novel therapeutics for bipolar depression and respiratory disease to focus on a therapy, aviptadil also known as ZYESAMI, for critical COVID-19 especially those with advanced comorbidities. This peptide hormone VIP enters the alveolar type II rare cell in the lung and blocks the replication of the SARs-CoV-2 virus and the production of inflammatory cytokines. Available through the FDA Expanded Access protocol, this drug is showing a nine-fold difference in survival and recovery from respiratory failure compared to patients with best available standard of care. @neurorxpharma #aviptadil #RLF-100 #ZYESAMI #coronavirus #COVID19 #drugdevelopment #pandemic $NRXP <a href="http://neurorxpharma.com" rel="noopener nofollow" target="_blank">NeuroRxPharma.com</a> <a href="http://empoweredpatientradio.com/treating-severe-respiratory-failure-in-covid-19-patients-with-dr-jonathan-javitt-neurorx-transcript" rel="noopener nofollow" target="_blank">Download the transcript here</a>

Treating Severe Respiratory Failure in COVID-19 Patients with Dr. Jonathan Javitt NeuroRx

Telcare Vice Chairman &amp; Founder, Jonathan Javitt explores why the FDA is allowing entrepreneurs more freedom than ever before and shares his experience pushing healthcare innovation forward with three different Presidential Administrations.

#25: Can Entrepreneurs and the FDA Finally Get Along? – Jonathan Javitt, Telcare